The New Flu Shot Isn’t Dead After All

Wednesday, February 18, 2026

After initially declining to review a new mRNA influenza vaccine, the U.S. Food and Drug Administration (FDA) has reversed course and will now evaluate Moderna’s application.

The vaccine, designed for adults age 50 and older, previously completed a 40,000-person clinical trial showing higher effectiveness in older adults compared with a commonly used flu shot. Regulators did not identify safety concerns. The earlier refusal stemmed from a dispute over the comparison standard: the trial used a standard-dose flu shot rather than the high-dose vaccine typically recommended for adults over 65. However, the FDA had previously approved the study design and did not identify any safety or efficacy concerns.

Moderna has now proposed a revised approval pathway: full approval for adults 50–64 and accelerated approval for those 65 and older with an additional post-market study. The FDA has accepted the application and is expected to issue a decision by August 5, 2026.

The change restores the possibility that the vaccine could become available later this year. For individuals with autoimmune disease and others at elevated infection risk, the significance is practical: vaccine availability determines the number of circulating respiratory infections and therefore the baseline exposure risk in daily life.

In Virginia, health officials reported 10 measles cases in early 2026, twice the total for all of 2025, underscoring how quickly vaccine-preventable diseases can resurge when immunity gaps occur. Virginia state health recommendations continue to emphasize adherence to the 2026 childhood immunization schedule, and school vaccination requirements remain unchanged.

Frequent changes in vaccine availability or recommendations can negatively affect well-being. Many people with autoimmune disease plan treatments, social activities, and exposure precautions around anticipated infection risk. When those expectations change, medical decisions may need to be revisited repeatedly.